This database contains 219 studies, archived under the term: "complications"
Click here to filter this large number of results.
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Cognitive subdomain responses to galantamine in Alzheimer’s disease
Song, Jihye,
Ahn, Inn Sook,
Kang, Hyo Shin,
Myung, Woojae,
Lee, Yujin,
Woo, Sook-young,
Ku, Hyoung Mo,
Hwang, Tae-Young,
Carroll, Bernard J.,
Kim, Doh Kwan
We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
Postoperative medical complications associated with anesthesia in older adults with dementia
Seitz, Dallas P.,
Gill, Sudeep S.,
Bell, Chaim M.,
Austin, Peter C.,
Gruneir, Andrea,
Anderson, Geoff M.,
Rochon, Paula A.
Objectives: To examine the association between anesthetic technique and postoperative complications in older adults with dementia undergoing hip fracture surgery.; Design: Population-based, retrospective cohort study.; Setting: Ontario, Canada.; Participants: All older adults with dementia who underwent surgery for hip fracture repair in Ontario, Canada, between April 1, 2003 and March 31, 2011.; Measurements: The baseline […]
An intensive exercise program improves motor performances in patients with dementia: translational model of geriatric rehabilitation
Schwenk, Michael,
Dutzi, Ilona,
Englert, Stefan,
Micol, William,
Najafi, Bijan,
Mohler, Jane,
Hauer, Klaus
Background: Translation of intensive exercise programs developed specifically for patients with dementia into clinical settings is lacking.; Objective: To determine if a progressive resistance and functional training program, previously evaluated in dementia outpatients, can be implemented in a geriatric inpatient setting in order to improve motor performances in patients with dementia.; Methods: Eligible patients in […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]